Third Harmonic Bio Inc Sustainability Reports
Third Harmonic Bio, Inc. was a clinical-stage biopharmaceutical company focused on developing therapies for allergic and inflammatory diseases. Its primary candidate was a highly selective oral small-molecule inhibitor targeting KIT for mast cell-mediated disorders.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
1 reports from 2022 to 2022
Company Profile
Third Harmonic Bio, Inc. was a clinical-stage biopharmaceutical company focused on developing therapies for allergic and inflammatory diseases. Its primary candidate was a highly selective oral small-molecule inhibitor targeting KIT for mast cell-mediated disorders.
Reports
1 total
Limited sustainability disclosure available
This company only publishes Annual Reports without dedicated sustainability sections.
Years